Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $11.6M | $233M | $375M | $485M | $38.0M | $28.8M | $75.1M |
| Revenue growth | — | 1907.9% | 60.9% | 29.4% | -92.2% | -24.2% | 160.6% |
| Operating income | -$4.12M | $156M | $204M | $217M | -$237M | -$315M | -$217M |
| Operating margin | -35.5% | 66.9% | 54.5% | 44.6% | -623.8% | -1091.7% | -289.0% |
| Net income | -$2.21M | $119M | $153M | $159M | -$146M | -$163M | -$146M |
| Net margin | -19.0% | 51.0% | 40.9% | 32.7% | -385.0% | -564.8% | -194.9% |
| EPS (diluted) | -$0.01 | $0.45 | $0.48 | $0.50 | -$0.51 | -$0.55 | -$0.49 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.69M | $22.7M | $245M | $277M | -$43.9M | -$109M | -$131M |
| Capital expenditures | $4.00M | $9.67M | $58.5M | $70.7M | $76.9M | $78.4M | $42.8M |
| Free cash flow | -$1.30M | $13.0M | $186M | $207M | -$121M | -$187M | -$174M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $594M | $476M | $387M | $133M | $156M | $129M |
| Total assets | — | $1.01B | $1.32B | $1.54B | $1.49B | $1.36B | $1.36B |
| Total liabilities | — | $175M | $293M | $308M | $336M | $304M | $390M |
| Shareholders' equity | $10.3M | $831M | $1.03B | $1.23B | $1.15B | $1.06B | $967M |
| Retained earnings | — | $114M | $268M | $426M | $280M | $117M | -$29.5M |
| Shares (wtd avg diluted) | 151M | 263M | 318M | 315M | 289M | 294M | 299M |
Every figure is extracted from AbCellera Biologics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.